Chitosan nanocarriers for non-coding RNA therapeutics: A review

Non-coding RNA (ncRNA)-based therapies entail delivering ncRNAs to cells to regulate gene expression and produce proteins that combat infections, cancer, neurological diseases, and bone abnormalities. Nevertheless, the therapeutic potential of these ncRNAs has been limited due to the difficulties in...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of biological macromolecules Vol. 263; no. Pt 1; p. 130361
Main Authors Karthik, S., Mohan, Sahithya, Magesh, Induja, Bharathy, Ashok, Kolipaka, Rushil, Ganesamoorthi, Srinidhi, Sathiya, K., Shanmugavadivu, Abinaya, Gurunathan, Raghav, Selvamurugan, N.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.04.2024
Subjects
biocompatible materials
Chitosan
Drug delivery
gene expression
Nanocarriers
non-coding RNA
Non-coding RNAs
polymers
Therapeutics
Tissue engineering
DD
lncRNAs
circRNAs
BBB
miRNAs
Drug delivery
CNV
GDH
HIF-1α
Mw
ncRNAs
N/P
TMCS
siRNAs
MSCs
UTR
ChT-TAT-H
TPP
CMC
PD-L1
AKT1
Nanocarriers
SPION
Cy5
dsRNA
FC-g-PEI
PBS
Non-coding RNAs
RNAi
DsiRNA
Tissue engineering
MS
STAT3
HTTR
NEAT1
BACE1
CS
CVD
PEG
Therapeutics
GTANP
HA
Chitosan
shRNAs
Online AccessGet full text
ISSN0141-8130
1879-0003
1879-0003
DOI10.1016/j.ijbiomac.2024.130361

Cover

More Information
Summary:Non-coding RNA (ncRNA)-based therapies entail delivering ncRNAs to cells to regulate gene expression and produce proteins that combat infections, cancer, neurological diseases, and bone abnormalities. Nevertheless, the therapeutic potential of these ncRNAs has been limited due to the difficulties in delivering them to specific cellular targets within the body. Chitosan (CS), a biocompatible cationic polymer, interacts with negatively charged RNA molecules to form stable complexes. It is a promising biomaterial to develop nanocarriers for ncRNA delivery, overcoming several disadvantages of traditional delivery systems. CS-based nanocarriers can protect ncRNAs from degradation and target-specific delivery by surface modifications and intracellular release profiles over an extended period. This review briefly summarizes the recent developments in CS nanocarriers' synthesis and design considerations and their applications in ncRNA therapeutics for treating various diseases. We also discuss the challenges and limitations of CS-based nanocarriers for ncRNA therapeutics and potential strategies for overcoming these challenges.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0141-8130
1879-0003
1879-0003
DOI:10.1016/j.ijbiomac.2024.130361